Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...

Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...

George Tidmarsh and Vinay Prasad have taken leadership roles at CDER and CBER, respectively, impacting FDA's drug and ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University's College ...

Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after ...

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

A 5-year interim analysis of the PERCEIVE real-world study showed sustained improvement of light sensitivity in patients ...